My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

Brady Johnson Biography and Net Worth

VP of Cidara Therapeutics

Brady Johnson occupies the position of Chief Accounting Officer & VP-Finance at Cidara Therapeutics, Inc.

How do I contact Brady Johnson?: The corporate mailing address for Mr. Johnson and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Brady Johnson's contact information.
Has Brady Johnson been buying or selling shares of Cidara Therapeutics?: Brady Johnson has not been actively trading shares of Cidara Therapeutics in the last ninety days. Most recently, Brady Johnson sold 32 shares of the business's stock in a transaction on Monday, March 21st. The shares were sold at an average price of $16.20, for a transaction totalling $518.40. Learn More on Brady Johnson's trading history.
Who are Cidara Therapeutics' active insiders?: Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), and Leslie Tari (Insider). Learn More on Cidara Therapeutics' active insiders.
Are insiders buying or selling shares of Cidara Therapeutics?: In the last twelve months, Cidara Therapeutics insiders bought shares 1 times. They purchased a total of 8,000 shares worth more than $105,680.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 3,944 shares worth more than $51,223.36. The most recent insider tranaction occured on September, 11th when insider Taylor Sandison sold 924 shares worth more than $10,755.36. Insiders at Cidara Therapeutics own 7.6% of the company. Learn More about insider trades at Cidara Therapeutics.
Information on this page was last updated on 9/11/2024.

Brady Johnson Insider Trading History at Cidara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/21/2022	Sell	32	$16.20	$518.40
3/11/2022	Sell	47	$14.20	$667.40
1/5/2022	Sell	20	$25.00	$500.00

Brady Johnson Buying and Selling Activity at Cidara Therapeutics

Cidara Therapeutics Company Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Today's Range

Now: $18.61

$17.17

$19.18

50 Day Range

MA: $12.00

$10.17

$15.63

2 Week Range

Now: $18.61

$10.00

$24.40

Volume

316,309 shs

Average Volume

39,540 shs

Market Capitalization

$131.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99